Genetic causes of a range of conditions not traditionally seen by clinical geneticists are increasingly being identifi ed. As these patients are treated across a variety of health departments, 'new' genetic services need to be developed and integrated into mainstream medical care. 1 The National Health Service (NHS) national genetics education centre recognised the need to raise awareness of genomics among health professionals in general, while providing in-depth knowledge for specialists. 2 However, the care of patients managed outside clinical genetics service teams currently remains highly inequitable as a result of limited awareness of genetic conditions.
Introduction
Genetic causes of a range of conditions not traditionally seen by clinical geneticists are increasingly being identifi ed. As these patients are treated across a variety of health departments, 'new' genetic services need to be developed and integrated into mainstream medical care. 1 The National Health Service (NHS) national genetics education centre recognised the need to raise awareness of genomics among health professionals in general, while providing in-depth knowledge for specialists. 2 However, the care of patients managed outside clinical genetics service teams currently remains highly inequitable as a result of limited awareness of genetic conditions.
Monogenic diabetes accounts for 2-3% of diabetes in the UK, 3,4 but remains poorly recognised despite the identifi cation and clinical characterisation of specifi c subtypes caused by mutations in single genes. Patients are misdiagnosed as having type 1 or type 2 diabetes in around 80% of cases 5 and are consequently inappropriately treated. Ensuring the correct diagnosis is important because most can be successfully treated with tablets even after years of insulin injections. 6,7 Similar issues have been identifi ed in other conditions: familial hypercholesterolaemia remains undiagnosed in approximately 85% of cases 8 and, in inherited cardiovascular conditions, a 10-to 20-fold variation in referral and genetic testing rates between different UK regions has been reported. 9 Effective mechanisms are therefore required to ensure that affected individuals have access to testing and specialist services, 10 and the need for education of professionals involved in the care of individuals with such genetic conditions is clear.
The monogenic diabetes team at the Royal Devon and Exeter NHS Foundation Trust and University of Exeter Medical School has led research into monogenic diabetes since 1995 and has established diagnostic and clinical services with a UK-wide NHS genetic testing service in 2000 (Fig 1) . In the UK, 483 cases of monogenic diabetes had been confi rmed by molecular genetic testing by the end of 2001, most of whom had been collected via research cohorts. However, there are clearly large numbers of patients who remained misdiagnosed due to unfamiliarity with monogenic diabetes because, if monogenic diabetes accounts for 1% of all diabetes, the minimum prevalence in the UK is reported to be approximately 6,000 cases or 108 per million. 5 Identifying those with monogenic diabetes allows not only correct diagnosis and treatment, including cessation of insulin injections in most, but also genetic counselling about the risk to children, the likely progression of the condition and appropriate screening for family members.
In response to this widespread lack of knowledge of monogenic diabetes, the authors developed the genetic diabetes nurse (GDN) project. This innovative project has been running since 2002 and is a national network of highly trained diabetes specialist nurses (DSNs) (Fig 2) who provide local expertise in monogenic diabetes across the UK, effectively and rapidly integrating new genetic knowledge into clinical care. 11 This project was recognised as an exemplar in the Department of Health's White Paper, Our Inheritance, Our Future, for building genetics into mainstream services. 12 The current paper evaluates 10 years of this national network, aims to assess whether this educational scheme resulted in increased diagnosis of monogenic diabetes and illustrates how this project could be used as a model for the effective translation of genetic knowledge into clinical care across a range of conditions. As this describes a service evaluation, ethical approval was not required.
Establishing the genetic diabetes nurse service
Initial funding from the Department of Health to increase the integration of genetics into clinical care enabled the GDN project to be developed. 13 The GDN posts were advertised through word of mouth via clinicians who had previously referred patients to the diagnostic genetic testing service and interested DSNs were identifi ed. The nurses were seconded for one session (3.5 hours) per week to the project and trusts reimbursed their salary for these hours and associated travel costs. Each nurse was initially seconded to the role for a period of 12 months; this was continued subject to satisfactory progress and achievement. The GDNs remain embedded within their diabetes clinical teams as DSNs but are allocated a geographical region to cover as part of their role. Additional funding was later obtained from the charity Diabetes Foundation and the Scottish Executive, which enabled the project to increase the network of GDNs with ten intakes of new nurses over the next 10 years.
The role of the genetic diabetes nurses
The GDNs are trained as regional experts and increase knowledge and awareness of monogenic diabetes by disseminating information through presentations to healthcare professionals across the country. The GDNs aim to aid identifi cation of patients who may have monogenic diabetes, increase numbers of referrals for genetic testing and ensure accurate diagnosis through positive molecular genetic test results. GDNs also guide management and treatment of patients with monogenic diabetes and provide ongoing support to families and clinicians.
Genetic diabetes nurse training
Introductory study days (2 days) cover basic topics relating to genetics and monogenic diabetes, and ongoing study days (1.5 days every 4 months) include in-depth sessions on these topics as well as updates as they occur (Fig 3) . The sessions are given by the multidisciplinary Exeter team of doctors, scientists, nurses and genetic counsellors. PowerPoint slides from these sessions are provided for GDNs to use in presentations to healthcare teams within their regions.
GDNs have email and phone access to the authors and Exeter colleagues for support and guidance about clinical cases. GDNs who are new in post are also allocated a more experienced GDN as a mentor; this person can provide additional assistance. Interim analysis indicated that the GDN posts enabled DSNs to extend their skills 13 while increasing recognition and awareness of monogenic diabetes across the UK. 11 Quality control is ensured through discussions and feedback with M Shepherd and following measures of activity, presentations and referrals.
Aims
The authors aim to evaluate whether training specialist nurses is an effective means of disseminating genetic information into clinical care.
Methods
The effectiveness of the GDNs was measured by evaluating: the numbers of patients whom they referred for genetic testing and the proportion of these receiving a positive genetic test result, and their presentations to healthcare professionals and the services/support that they offered to families with a confi rmed diagnosis. GDNs were asked to complete feedback forms after each presentation given across their region, which provided a summary of the location, staff present and GDNs' refl ections on the session, any diffi culties encountered and followup organised. The GDNs provided evaluation forms for the attendees to complete which scored the presentation on educational value, quality and usefulness of the session. Feedback and evaluation forms were then collated and reviewed by the Exeter team.
The numbers of patients referred by the GDNs for genetic testing were monitored and the appropriateness of referrals, proportion of positive test results and numbers of affected family members tested were evaluated. GDNs were encouraged to initiate specialist monogenic clinics within their regions and the location and frequency of these clinics were recorded. GDNs supported patients during genetic testing and subsequent treatment change and provided details to the Exeter team. Ongoing assessment of the cases that the GDNs discussed and monitoring of their monthly activity were recorded. Review meetings have been held individually with all GDNs, and any GDNs underperforming when measured against these criteria or struggling with the complexity of the role, despite additional support and guidance, have had their posts discontinued.
Results
To date 52 GDNs have been trained in ten intakes since 2002.
Referrals for genetic testing
GDNs have helped increase yearly referral rates for genetic testing of diabetic patients (Fig 4) GDNs have also worked collaboratively across regions to organise study days for staff across wider geographical areas.
Development of services
As a result of their training, the GDNs have created 9 UK-wide specialist monogenic clinics, reviewing >1,000 individuals from 710 families in collaboration with local diabetologists, improving the care offered for patients with monogenic diabetes within these regions. The GDNs and clinicians review patients and families with known or suspected monogenic diabetes within these clinics. Patients can be referred from elsewhere and the monogenic clinics are a forum for training other local staff. 
Support for families
GDNs have supported more than 100 patients able to transfer from long-term insulin injections to sulfonylurea tablets after their genetic diagnosis. These patients were previously misdiagnosed as having type 1 diabetes and were inappropriately treated with unnecessary insulin injections. The role of the GDN was crucial in identifying these patients and ensuring a smooth transition from insulin injections to oral agents, leading to improvements not only in diagnosis and treatment, but also in the followup of other family members
Ongoing professional development of the genetic diabetes nurses
The GDN project has also provided opportunities for professional development. Five of the GDNs currently in post have gained further training at MSc level in genetic counselling, practical genetics and genetic science, which has enhanced their knowledge and credibility within the role. GDNs have presented posters and given talks at national and international conferences and published 13-21 as a consequence of their role.
Discussion
The GDN project has been successful in increasing awareness of monogenic diabetes across the UK, leading to better care, more appropriate treatment/family followup, and considerable cost savings for the NHS for those patients able to transfer from insulin to sulfonylureas. The project has recruited and trained a team of highly motivated GDNs who have been able to share their expertise in monogenic diabetes with a wide range of healthcare professionals across the UK. The ongoing training, as well as regular contact with the Exeter monogenic diabetes team, enables rapid distribution of genetic information after new discoveries. Although the GDN project costs are modest (<£100k/year), obtaining funding has been challenging because the GDNs work across regions and typical funding mechanisms are not transferable. National funding for very rare conditions, provided through specialist commissioning, was limited to diseases affecting fewer than 500 patients in the UK, and was therefore not applicable to monogenic diabetes. The Department of Health, the Diabetes Foundation and the Scottish Executive have all supported the project fi nancially; however, continued sustainable funding remains problematic.
The GDN project may be seen as a model for the translation of genetics into clinical care in other areas because the rapid increase in genetic knowledge cannot possibly be managed by the current resources of clinical genetics teams. Specialist nurses work across a range of conditions in which specifi c genetic causes of disease are now recognised, eg in cancer and cardiac services, so they could be trained using a similar innovative approach of ongoing regular training, developed and coordinated by a centre of excellence. Developing the skills of specialist nurses using this model of training and dissemination could be a cost-effective and successful means of rapidly increasing genetic knowledge into clinical care across the NHS. (See www.diabetesgenes.org for further information about genetic testing and the GDN network.) ■
